Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III clinical trial of TO-203 - Evaluation of efficacy and safety in pediatric patients with HDM-induced allergic rhinitis -

X
Trial Profile

Phase III clinical trial of TO-203 - Evaluation of efficacy and safety in pediatric patients with HDM-induced allergic rhinitis -

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
  • Indications Allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Torii Pharmaceutical
  • Most Recent Events

    • 25 Jul 2018 Results published in the Allergy
    • 16 Feb 2018 According to a ALK-Abello media release, based on the data from this trial Japanese Ministry of Health, Labour and Welfare,has approved to expand the use of ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet MITICURE™ to include paediatric allergic rhinitis patients.
    • 24 Mar 2017 According to a company media release, ALK announced that its partner for Japan, Torii Pharmaceutical Co., Ltd., has submitted an application to the Japanese Ministry of Health, Labour and Welfare, seeking to expand the use of ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet MITICURE™ to include paediatric allergic rhinitis patients. The new application is based on results from this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top